Chris Cornelison named interim Associate Vice President for Innovation and Commercialization

KENNESAW, Ga. | September 6, 2023

Kennesaw State University microbiology professor Chris Cornelison will serve as interim Associate Vice President for Innovation and Commercialization, effective September 1.

Cornelison, who for the past three years has served as Director of  Intellectual Property Development, will work closely with Vice President for Research Karin Scarpinato on a variety of Office of Research initiatives, focusing on applied research and venture creation.

Chris Cornelison headshot

“Chris has demonstrated his entrepreneurial expertise through the procurement of several externally funded grants, in addition to the support infrastructure he has built for faculty here at KSU,” Scarpinato said. “Moving forward, he will be instrumental in working to expand our industry relations and commercialization portfolio.”

Cornelison will primarily focus on growing applied research and entrepreneurship across the university, a focus that includes  Hatchbridge, a business incubator that launched earlier this year and assists local entrepreneurs in growing their businesses by offering resources such as guidance, office space and programming.

With many academic units at KSU already engaged in applied research, Cornelison aims to direct talent across both campuses to maximize the university’s impact on the region. Developing collaborations with Hatchbridge, Coles College of Business, Research Development and Strategic Initiatives, University Advancement, Career Planning and Development, and Government Relations will be crucial in the university reaching its full potential as a source for innovative solutions with market potential.

In addition to Intellectual Property Development duties, Cornelison also operates the  BioInnovation Laboratory, which currently has seven active external grants, highlighted by the lab’s work on white-nose syndrome in bats and the development of novel therapeutic interventions.

The lab is also active in  culinary mushroom cultivation, which includes technology that is licensed to MycoLogic, a startup Cornelison founded with postdoctoral researcher Kyle Gabriel that has garnered numerous awards in startup competitions. 

MycoLogic finished first this summer at the Georgia AgTech Summit, and earlier this year, the KSU-based startup was a finalist at the Ag Innovation Challenge sponsored by the American Farm Bureau Federation.

Cornelison’s entrepreneurial background will be essential in performing the duties of interim Associate Vice President for Innovation and Commercialization.

“As a founder of a startup at KSU, I have learned what it means to be a faculty entrepreneur,” Cornelison said. “I am thrilled to have the opportunity to support my colleagues in their pursuit of entrepreneurial activities that allow the world to benefit from the great research they are doing.”

Other BioInnovation Laboratory projects include the production of pigments from agricultural and industrial waste materials by using food-grade fungi as biocatalysts, a project that recently received venture development funding and was the research focus of 2023 Birla Carbon Summer Scholar Mark Sheehan.

Cornelison earned his B.S. in microbiology at the University of Georgia in 2009, and his M.S. and Ph.D. in applied and environmental microbiology at Georgia State University in 2011 and 2013, respectively.

It was at Georgia State University while working in the laboratory of Dr. Sidney A. Crow that Cornelison developed an interest in how research intersects with commercialization. 

“I was able to see how to build an applied research portfolio and learned about many of the ways in which research products reach their full potential via commercialization,” Cornelison said. “As a postdoc, I was part of an NSF I-Corps team. This further reinforced my desire to be active in driving academic innovations to market and gave me an appreciation for understanding product-market fit and the needs of customers.”

Cornelison carried those lessons into his role of Director of Intellectual Property Development, where he built KSU’s technology transfer operations from the ground floor by creating the Innovation Launch Pad to train faculty and student inventors in lean startup methodology and customer discovery, established the Innovation Seed Grant Program to support inventors in advancing their innovation during the provisional year, and created the KSU Quick Start Licensing Program to allow faculty to quickly obtain freedom to operate for commercial utilization of their innovations.

“Technology transfer at KSU is far more advanced than it was three years ago, and I am proud of the progress we have made,” Cornelison said.

— By David Roberts

Source: https://research.kennesaw.edu/roc/stories/cornelison_avp_innovation_commercialization.php

Georgia Life Sciences Weighs In on PBM and 340B Policy

October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →

Georgia Life Sciences Joins National Coalition Calling for PAHPA Reauthorization

September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.

Georgia Life Sciences Urges Protection of Patient Access as Georgia Implements Medicaid Changes

September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
MORE POSTS